Verrica Pharmaceuticals Stock Investor Sentiment

VRCA Stock  USD 0.99  0.01  1.00%   
About 57% of all Verrica Pharmaceuticals' investors are looking to take a long position. The analysis of overall sentiment of trading Verrica Pharmaceuticals stock suggests that some investors are interested at this time. The current market sentiment, together with Verrica Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Verrica Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  

Verrica Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Verrica Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
Verrica Pharmaceuticals Inc. Shares Sold by Kornitzer Capital Management Inc. KS - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Canadian securities regulators provide update on interim approach to value-referenced crypto assets
Yahoo News
over six months ago at news.google.com         
Verrica Pharmaceuticals Buy Rating Reaffirmed at Needham Company LLC - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Verrica Pharmaceuticals Receives Buy Rating from Needham Company LLC - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Strong week for Verrica Pharmaceuticals shareholders doesnt alleviate pain of three-year loss
Yahoo News
over six months ago at benzinga.com         
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Confere...
benzinga news
over six months ago at www.macroaxis.com         
Acquisition by Paul Manning of 4761904 shares of Verrica Pharmaceuticals at 2.1 subject to Rule 16b-...
Macroaxis News
over six months ago at simplywall.st         
Verrica Pharmaceuticals Inc.s Shift From Loss To Profit
Simply Wall St News at Macroaxis
over six months ago at finance.yahoo.com         
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Li...
Yahoo News
over six months ago at globenewswire.com         
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Li...
Macroaxis News: globenewswire.com
over six months ago at investing.com         
Verrica gains FDA exclusivity for skin disease drug YCANTH
Investing News at Macroaxis
over six months ago at news.google.com         
Financial Survey Verrica Pharmaceuticals and Pharvaris - Defense World
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Ted White of 225000 shares of Verrica Pharmaceuticals at 4.8 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Fmr LLC Has 5.85 Million Position in Verrica Pharmaceuticals Inc. - Defense World
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Verrica Pharmaceuticals Inc. Expected to Earn FY2028 Earnings of 1.83 Per Share
news
Far too much social signal, news, headlines, and media speculation about Verrica Pharmaceuticals that are available to investors today. That information is available publicly through Verrica media outlets and privately through word of mouth or via Verrica internal channels. However, regardless of the origin, that massive amount of Verrica data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Verrica Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Verrica Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Verrica Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Verrica Pharmaceuticals alpha.

Verrica Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Prygocki Mark A Sr of 20000 shares of Verrica Pharmaceuticals at 8.78 subject to Rule 16b-3
09/10/2024
2
Disposition of 2675611 shares by Manning Paul B of Verrica Pharmaceuticals subject to Rule 16b-3
09/19/2024
3
Verrica Pharmaceuticals CFO resigns to pursue new opportunity - Investing.com
09/27/2024
4
Verrica Pharmaceuticals to lay off about half of its staff in restructuring
10/02/2024
5
Verrica downgraded to hold by Needham, cash position cited
10/03/2024
6
Verrica Pharmaceuticals Strives for Nasdaq Compliance - TipRanks
10/08/2024
7
Verrica Pharmaceuticals Price Target Lowered to 10.00 at TD Cowen
10/21/2024
8
Insider Trading
11/05/2024
9
This Super Micro Computer Analyst Turns Bearish Here Are Top 5 Upgrades For Wednesday
11/06/2024
10
Verrica Announces Pricing of 42.0 Million Public Offering
11/21/2024

Complementary Tools for Verrica Stock analysis

When running Verrica Pharmaceuticals' price analysis, check to measure Verrica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verrica Pharmaceuticals is operating at the current time. Most of Verrica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Verrica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verrica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Verrica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities